Avalanche (AVAX) has been stuck in a consolidation phase, trading within a narrow band of $20 to $26 over the past several weeks. Despite a few attempts to push higher, momentum has remained limited, leaving the token in a state of indecision. The price action reflects hesitation on both sides of the market, with neither […]
AVAX Price
AVAX Breaks Out of Falling Wedge, Surges 9% Toward $40
Avalanche (AVAX) has seized market sentiment with a dramatic rise in price and boosted trading volume. As of the time of analysis, the price of AVAX has reached $25.07, alongside a high 24-hour trading volume of $786 million. The market cap for AVAX now stands at about $10.55 billion, reflecting its status as a top […]
Avalanche Under Pressure: Will AVAX Rebound or Drop Below $18 in 2025?
Avalanche (AVAX) is now trading at $19.48, registering a slight dip of 0.60% from the previous 24 hours. Yet, its trading volume spiked to $288.95 million, 51.52% higher, indicating renewed speculative behavior. In spite of this short-term volume spike, AVAX has declined by 7.68% in the last week, reflecting ongoing short-term bearishness. Technical indicators for […]
Avalanche (AVAX) Showing Signs of Recovery: Analyst Set Targets at $34 to $64 Range
Avalanche (AVAX) shows remarkable resilience by maintaining support levels and gearing up for a potential upward surge. Despite a significant 12% decline over the past week, largely in line with prevailing bearish market sentiment. Avalanche remains a focal point of optimism among analysts; they foresee a substantial uptrend in AVAX’s price trajectory. Amidst a broader […]
Avalanche (AVAX) Surges 14%: Analyst Points Towards Potential Upswing
Cryptocurrency analyst Jonathan Carter has brought attention to recent movements in Avalanche (AVAX), indicating a possible upswing for the digital asset. AVAX has retraced toward an ascending support range between $30 and $31, signaling the initiation of a consolidation phase and suggesting stability in its price action. Carter’s analysis highlights that Avalanche (AVAX) is testing […]